Ascendis Pharma A/S (NASDAQ:ASND) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report published on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $290.00 price objective on the biotechnology company’s stock.

Several other brokerages have also weighed in on ASND. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research report on Wednesday, March 4th. Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Wolfe Research restated an “outperform” rating and set a $260.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Oppenheimer lifted their price objective on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Finally, Wedbush boosted their target price on shares of Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $289.89.

Ascendis Pharma A/S Stock Up 2.2%

Shares of ASND stock opened at $231.02 on Monday. The company has a market cap of $14.32 billion, a P/E ratio of -52.50 and a beta of 0.43. The business has a 50 day moving average of $224.60 and a two-hundred day moving average of $211.59. Ascendis Pharma A/S has a 52 week low of $124.06 and a 52 week high of $248.60.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The firm had revenue of $290.38 million during the quarter, compared to analyst estimates of $285.35 million. Analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors have recently bought and sold shares of the stock. Vise Technologies Inc. bought a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth about $222,000. Geode Capital Management LLC increased its stake in shares of Ascendis Pharma A/S by 5.1% during the second quarter. Geode Capital Management LLC now owns 60,804 shares of the biotechnology company’s stock valued at $10,495,000 after acquiring an additional 2,953 shares during the period. Creative Planning increased its stake in shares of Ascendis Pharma A/S by 48.0% during the second quarter. Creative Planning now owns 5,383 shares of the biotechnology company’s stock valued at $929,000 after acquiring an additional 1,746 shares during the period. Cetera Investment Advisers bought a new stake in Ascendis Pharma A/S during the second quarter worth approximately $552,000. Finally, Nomura Asset Management Co. Ltd. lifted its position in Ascendis Pharma A/S by 20.4% in the second quarter. Nomura Asset Management Co. Ltd. now owns 25,645 shares of the biotechnology company’s stock worth $4,426,000 after purchasing an additional 4,343 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.